Status:
RECRUITING
Effect of Psychedelic VR-augmented Therapy on Patients With Clinical Depression
Lead Sponsor:
University of Tartu
Collaborating Sponsors:
Confido Medical Centre
Conditions:
Depression
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Research has demonstrated that psychedelic compounds possess significant therapeutic potential for a variety of disorders, including depression. Despite these findings, the underlying mechanisms drivi...
Eligibility Criteria
Inclusion
- Persistent depressive symptoms observed during the initial screening and confirmed at baseline, as determined through a comprehensive psychiatric evaluation.
- Provision of written informed consent by the participant.
- Fluent in Estonian as a native language.
Exclusion
- Presence of significant impairments in vision, hearing, or balance.
- Active suicidal ideation or current engagement in self-harm behaviors. Note: Individuals meeting this criterion will be directed to suitable crisis intervention services.
- Established diagnosis of bipolar disorder.
- Manifestation of psychotic symptoms.
- History of schizophrenia, either personally or within two generations of the family lineage.
- Ongoing diagnosis of epilepsy, dementia, or any other neurological condition that could interfere with the effective utilization of virtual reality (VR) technology.
- Susceptibility to motion sickness.
Key Trial Info
Start Date :
November 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06174285
Start Date
November 6 2023
End Date
June 30 2026
Last Update
March 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Confido Medical Centre
Tallinn, Harju, Estonia, 10138